Pfizer Announces New Investor Relations Leader
July 19 2021 - 6:45AM
Business Wire
Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo
has joined the company as Senior Vice President and Chief Investor
Relations Officer, reporting to Chief Corporate Affairs Officer
Sally Susman. Mr. Stevo succeeds Chuck Triano, Senior Vice
President, Investor Relations, who previously announced his intent
to retire after a successful 13-year period at Pfizer and a nearly
35-year career interacting with the global investment community.
Mr. Triano will stay on through the end of September to help with
the transition.
“We would like to thank Chuck for his many contributions to the
company and for successfully elevating Pfizer’s investor relations
function to a best-in-class,” said Albert Bourla, Chairman and
Chief Executive Officer, Pfizer. “His passion for the company and
for our industry will be missed. We wish him all the best in this
new chapter of his life.”
“As the new head of Investor Relations, Chris brings a wealth of
experience with buy-side equity analysts and a strong network of
relationships across the investment community. His deep knowledge
of the healthcare industry will be a great asset as we continue to
advance our innovative pipeline to deliver breakthrough therapies
and vaccines to patients and long-term value for shareholders,”
Bourla added.
Mr. Stevo has held leadership positions in buy-side healthcare
investing for more than two decades, most recently serving as Head
of Investor Relations for Alexion Pharmaceuticals. Prior to his
role at Alexion, Mr. Stevo served as senior equity analyst for
Amundi US responsible for a portfolio of U.S. healthcare stocks
covering all sub-sectors; and before Amundi US, he held numerous
leadership roles with Putnam Investments specializing in
international healthcare, including the co-management of a $1.2
billion AUM global healthcare fund.
Mr. Stevo graduated University of Pennsylvania’s Wharton School
with a Bachelor of Science degree in economics and earned his MBA
from University of Chicago’s Booth School of Business. He is also a
designated Chartered Financial Analyst.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of July 19, 2021. The Company assumes no obligation
to update forward-looking statements contained in this release as a
result of new information or future events or developments.
This release contains forward-looking information about, among
other things, our efforts to advance our innovative pipeline to
deliver breakthrough therapies and vaccines to patients and
long-term value for shareholders that are subject to substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2020 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005167/en/
Media Contact:
Amy Rose +1 (212) 733-1226 Amy.Rose@Pfizer.com
Investor Contact:
Chuck Triano +1 (212) 733-3901 Charles.Triano@Pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024